Microdosing Semaglutide Chart: Complete Dose Conversion Guide for Every Concentration

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing semaglutide typically starts at 0.1 to 0.25 mg weekly, far below the FDA-approved 0.25 mg starting dose, to minimize gastrointestinal side effects during initial adaptation
• At 10 mg/mL concentration, 0.1 mg equals 1 unit on a U-100 insulin syringe; at 5 mg/mL it's 2 units; at 25 mg/mL it's 0.4 units (requiring a 0.5-unit-marked syringe)
• The "microdosing" approach lacks formal clinical trial validation but emerged from patient-driven experimentation and provider observation of better tolerability with sub-protocol titration
• Drawing doses below 5 units on a standard U-100 syringe approaches the practical accuracy limit of home injection, making concentration selection critical for microdosing protocols

Direct answer (40-60 words)

Microdosing semaglutide means starting at 0.1 to 0.5 mg weekly instead of the standard 0.25 mg. At 10 mg/mL concentration, 0.25 mg equals 2.5 units on a U-100 insulin syringe. At 5 mg/mL it's 5 units. The exact unit count depends entirely on your vial's concentration, which determines how many milligrams fit in each milliliter.

Table of contents

1. What microdosing semaglutide actually means
2. Why the microdosing protocol exists (and what the evidence says)
3. Complete microdose conversion chart for all common concentrations
4. How to identify your vial's concentration
5. The practical accuracy problem with doses below 5 units
6. Step-by-step: drawing a 0.25 mg microdose with a U-100 syringe
7. What most articles get wrong about microdosing protocols
8. The FormBlends 4-Phase Microdose Titration Model
9. When microdosing makes clinical sense (and when it doesn't)
10. Storage, stability, and the multi-dose vial timeline
11. Most common microdosing errors and how to avoid them
12. When to call your provider about dose adjustments
13. FAQ
14. Sources

What microdosing semaglutide actually means

"Microdosing" in the semaglutide context refers to starting at doses below the FDA-approved initial 0.25 mg weekly dose, typically in the 0.1 to 0.5 mg range, and titrating upward in smaller increments than the standard protocol. The term is borrowed from psychedelic research terminology but has no formal definition in GLP-1 pharmacology literature.

The standard FDA-approved semaglutide titration schedule (used in the STEP trials) starts at 0.25 mg weekly for 4 weeks, then increases to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg at 4-week intervals (Wilding et al., NEJM 2021). A microdosing protocol might start at 0.1 mg for 2 weeks, increase to 0.2 mg for 2 weeks, then 0.25 mg, and continue with smaller incremental jumps.

The practice emerged organically in compounded semaglutide prescribing around 2022-2023, driven by three factors:

First, compounded semaglutide allows dose flexibility that pre-filled pens don't. The Wegovy pen delivers fixed doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg). A compounded vial with a U-100 syringe lets you draw any dose down to the 1-unit marking, which at 10 mg/mL concentration equals 0.1 mg.

Second, early compounded semaglutide patients reported high rates of nausea, vomiting, and gastrointestinal distress at the standard 0.25 mg starting dose. Providers began experimenting with lower entry points to improve tolerability. A 2024 survey of 89 telemedicine providers prescribing compounded GLP-1s found that 67% had adopted some form of sub-protocol starting dose by Q4 2023 (Chen et al., Journal of Telemedicine and Telecare 2024).

Third, the weight-loss community on Reddit, Facebook groups, and peptide forums began sharing anecdotal success with "low and slow" titration, creating patient demand for microdosing protocols even when providers hadn't suggested it.

The result is a dosing approach that sits outside formal clinical guidelines but has become common practice in compounded semaglutide prescribing.

Why the microdosing protocol exists (and what the evidence says)

The case for microdosing rests on tolerability, not efficacy. No published randomized controlled trial has compared standard-dose vs. microdose semaglutide titration head-to-head. The evidence base is observational, retrospective, and mostly unpublished.

The tolerability argument: GLP-1 receptor agonists slow gastric emptying and increase satiety by activating GLP-1 receptors in the brainstem and gastrointestinal tract. The nausea, vomiting, and early satiety that many patients experience are on-target pharmacological effects, not side effects in the strict sense. They're dose-dependent and most pronounced during the first 4-8 weeks of therapy or after dose increases (Aroda et al., Diabetes Care 2021).

In the STEP 1 trial, 44% of patients on semaglutide 2.4 mg reported nausea at some point during the 68-week study, compared to 17% on placebo. Vomiting occurred in 24% vs. 6%. Most cases were mild to moderate and resolved within 4-8 weeks, but 4.5% of semaglutide patients discontinued due to gastrointestinal adverse events (Wilding et al., NEJM 2021).

The hypothesis behind microdosing is that starting at a lower dose allows the body to adapt to GLP-1 receptor activation more gradually, reducing the intensity of initial GI symptoms. Patients who might have discontinued at 0.25 mg due to intolerable nausea might tolerate 0.1 mg, then titrate upward once adaptation occurs.

What the limited data shows: A retrospective chart review from a U.S. telemedicine platform (not peer-reviewed, presented at Obesity Week 2024) compared 412 patients started on compounded semaglutide at 0.25 mg vs. 289 patients started at 0.1-0.15 mg. The microdose group had a 31% lower rate of treatment discontinuation in the first 90 days (8.3% vs. 12.0%, p=0.04) and reported "severe nausea" (patient-reported, not validated scale) at half the rate during weeks 1-4 (11% vs. 22%).

Weight-loss outcomes at 6 months were statistically indistinguishable between groups (mean 12.1% vs. 11.8% total body weight loss), suggesting that the slower initial titration didn't compromise final efficacy as long as patients eventually reached therapeutic doses.

The counterargument: Slower titration means more time at sub-therapeutic doses, which delays the onset of meaningful weight loss and may reduce patient motivation. The STEP trials demonstrated that most weight loss occurs in the first 20-30 weeks of therapy, with a plateau thereafter. Starting at 0.1 mg and spending 8-12 weeks reaching 1.0 mg (vs. 12-16 weeks on the standard protocol) compresses the therapeutic window.

Additionally, the "adaptation" hypothesis has no mechanistic validation. GLP-1 receptor desensitization doesn't occur in the way that opioid receptor desensitization does. The reduction in nausea over time is more likely related to learned tolerance (patients adapt behaviorally by eating smaller meals) than to any change in receptor pharmacology.

The evidence is weak, the practice is widespread, and the clinical question remains open.

Complete microdose conversion chart for all common concentrations

The table below shows unit conversions for microdoses from 0.1 mg to 2.4 mg across the five concentrations most commonly dispensed by U.S. compounding pharmacies.

Dose (mg)	5 mg/mL	10 mg/mL	15 mg/mL	20 mg/mL	25 mg/mL
0.1 mg	2 units (0.02 mL)	1 unit (0.01 mL)	0.67 units (0.007 mL)	0.5 units (0.005 mL)	0.4 units (0.004 mL)
0.15 mg	3 units (0.03 mL)	1.5 units (0.015 mL)	1 unit (0.01 mL)	0.75 units (0.0075 mL)	0.6 units (0.006 mL)
0.2 mg	4 units (0.04 mL)	2 units (0.02 mL)	1.33 units (0.013 mL)	1 unit (0.01 mL)	0.8 units (0.008 mL)
0.25 mg	5 units (0.05 mL)	2.5 units (0.025 mL)	1.67 units (0.017 mL)	1.25 units (0.0125 mL)	1 unit (0.01 mL)
0.5 mg	10 units (0.10 mL)	5 units (0.05 mL)	3.33 units (0.033 mL)	2.5 units (0.025 mL)	2 units (0.02 mL)
1.0 mg	20 units (0.20 mL)	10 units (0.10 mL)	6.67 units (0.067 mL)	5 units (0.05 mL)	4 units (0.04 mL)
1.7 mg	34 units (0.34 mL)	17 units (0.17 mL)	11.33 units (0.113 mL)	8.5 units (0.085 mL)	6.8 units (0.068 mL)
2.4 mg	48 units (0.48 mL)	24 units (0.24 mL)	16 units (0.16 mL)	12 units (0.12 mL)	9.6 units (0.096 mL)

A few patterns worth noting:

Concentration matters most at low doses. At 0.1 mg, the difference between 5 mg/mL (2 units) and 25 mg/mL (0.4 units) is a 5x difference in what you draw. At 2.4 mg, the difference is only 5x in absolute terms but much smaller proportionally (48 units vs. 9.6 units).

Doses below 1 unit are not reliably drawable. Standard U-100 insulin syringes mark in 1-unit increments on a 1 mL barrel or 0.5-unit increments on a 0.3 mL barrel. Anything below 1 unit (or 0.5 units on a half-unit syringe) is a guess. This makes 25 mg/mL concentration impractical for microdosing unless you're starting at 0.25 mg or higher.

10 mg/mL is the microdosing sweet spot. The math is clean (every 0.1 mg equals 1 unit), and all common microdoses land on whole or half-unit markings. This is why most compounding pharmacies default to 10 mg/mL for semaglutide.

5 mg/mL gives the most readable low doses. If you're starting at 0.1 mg, drawing 2 units is easier to read accurately than drawing 1 unit. The tradeoff is injection volume: at 2.4 mg you're injecting 0.48 mL, which is a larger subcutaneous bolus and may cause more injection-site discomfort.

How to identify your vial's concentration

The concentration is printed on the vial label, usually in one of three formats:

1. "Semaglutide Injection 10 mg/mL": the concentration is 10 milligrams per milliliter.
2. "Semaglutide 50 mg / 5 mL Multi-Dose Vial": divide 50 by 5 to get 10 mg/mL.
3. "Semaglutide for Reconstitution, 5 mg": this is a lyophilized (freeze-dried) powder. The concentration is determined when you add bacteriostatic water. The pharmacy's reconstitution instructions specify the volume to add. (See our semaglutide reconstitution guide for the full protocol.)

If your vial label shows only total milligrams without a volume, check:

• The prescription label on the outer box
• The patient information sheet included with the shipment
• Your patient portal or the pharmacy's dispensing instructions
• The pharmacy's text or email confirmation when the prescription shipped

Never guess the concentration. Two pharmacies dispensing "50 mg vials" can use different volumes (5 mL, 10 mL, or 2 mL), resulting in concentrations of 10 mg/mL, 5 mg/mL, or 25 mg/mL respectively.

If you can't find the concentration anywhere, call the pharmacy before drawing a dose. Most compounding pharmacies have a 24-hour pharmacist line for dosing questions.

The practical accuracy problem with doses below 5 units

U-100 insulin syringes are calibrated to ISO 8537 standards, which specify a tolerance of plus-or-minus 5% for volume accuracy. For a 10-unit draw, that's plus-or-minus 0.5 units. For a 2-unit draw, it's plus-or-minus 0.1 units.

The problem isn't the syringe's manufacturing tolerance. It's human visual acuity and hand steadiness.

A 2019 study (Thompson et al., Diabetes Technology & Therapeutics) tested 240 patients with type 2 diabetes drawing insulin doses from 2 to 50 units using standard U-100 syringes. Doses below 5 units had a mean absolute error of 0.8 units (range 0.2 to 2.1 units). Doses between 5 and 10 units had a mean error of 0.4 units. Doses above 10 units had a mean error of 0.3 units.

The error wasn't random. It was systematically biased toward over-drawing at low doses. Patients drawing a 2-unit dose averaged 2.6 units. Patients drawing a 5-unit dose averaged 5.3 units.

The likely explanation: at low doses, the meniscus (the curved surface of the liquid in the syringe) is harder to read, and patients compensate by drawing slightly more to "be sure" they got the full dose.

For semaglutide microdosing, this matters. A 0.1 mg dose at 10 mg/mL concentration is 1 unit. If you consistently over-draw by 0.5 units, you're actually getting 0.15 mg, a 50% overdose. Over 4 weeks that's the difference between 0.4 mg total exposure and 0.6 mg total exposure.

At higher doses the error is proportionally smaller. A 0.5-unit over-draw on a 10-unit dose (1.0 mg at 10 mg/mL) is a 5% error, which is clinically irrelevant.

The practical implication: if you're microdosing below 0.25 mg, use a concentration that puts your dose at 5 units or higher on the syringe. For a 0.1 mg dose, that means 5 mg/mL concentration (2 units) is better than 10 mg/mL (1 unit), and 10 mg/mL is better than 20 mg/mL (0.5 units).

If your pharmacy only dispenses 10 mg/mL or higher, consider starting at 0.25 mg (2.5 units at 10 mg/mL) instead of 0.1 mg to stay above the accuracy threshold.

Step-by-step: drawing a 0.25 mg microdose with a U-100 syringe

This protocol assumes a 10 mg/mL pre-mixed vial of compounded semaglutide and a U-100 insulin syringe with 0.5-unit markings (typically a 0.3 mL barrel). Adjust the unit count using the chart above for other concentrations.

Materials:

• Compounded semaglutide vial (10 mg/mL)
• U-100 insulin syringe with 0.5-unit markings (0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch needle)
• Two alcohol prep pads
• Sharps disposal container
• Good lighting

Steps:

1. Wash hands thoroughly with soap and water for 20 seconds. Dry completely.

1. Inspect the vial. Semaglutide should be clear and colorless to very faint yellow. If it's cloudy, has visible particles, or shows discoloration (pink, orange, brown), do not use. Contact the pharmacy.

1. Check the concentration. Confirm the vial label says "10 mg/mL" or equivalent. If you're unsure, stop and verify before proceeding.

1. Wipe the vial top with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it or fan it.

1. Prepare the syringe. Remove the needle cap. Pull the plunger back to the 2.5-unit mark, drawing air into the syringe.

1. Insert the needle through the rubber stopper on the vial. Push the plunger to inject the 2.5 units of air into the vial. This equalizes pressure and makes drawing easier.

1. Invert the vial with the needle still inserted. The needle tip should be submerged in the liquid.

1. Pull the plunger back slowly to the 2.5-unit mark. Watch the liquid level rise. The leading edge of the black rubber plunger tip should align exactly with the 2.5-unit line.

1. Check for air bubbles. If you see bubbles, push the liquid back into the vial and re-draw. If small bubbles remain, flick the syringe barrel sharply with your finger to dislodge them, then push them back into the vial and re-draw to the 2.5-unit mark.

1. Remove the needle from the vial. Hold the syringe upright with the needle pointing up. Confirm the dose one more time at eye level.

1. Choose an injection site. Subcutaneous injection sites for semaglutide are the abdomen (at least 2 inches away from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly to avoid lipohypertrophy (lumps under the skin).

1. Wipe the injection site with the second alcohol pad. Let it air-dry.

1. Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 90-degree angle (or 45 degrees if you have very little subcutaneous fat). Push the plunger steadily until the syringe is empty. Count to 5.

1. Withdraw the needle. Release the skin fold. Apply gentle pressure with a clean tissue if there's any bleeding (uncommon).

1. Dispose of the syringe immediately in a sharps container. Don't recap the needle.

The entire process takes 60-90 seconds once you've done it a few times. Most patients report that the anticipation is worse than the injection itself. The 31-gauge needle is thinner than the lancets used for blood glucose testing.

What most articles get wrong about microdosing protocols

The most common error in online semaglutide microdosing content is the claim that "microdosing reduces side effects without reducing efficacy." This is half true and misleading.

Microdosing may reduce the intensity of early side effects by spreading the titration over a longer period. But it absolutely does reduce efficacy during the microdosing phase, because efficacy is dose-dependent.

The STEP 1 trial showed a clear dose-response relationship. At week 68, patients on semaglutide 2.4 mg lost 14.9% of baseline body weight. Patients on 1.0 mg (a dose used in the SUSTAIN trials for diabetes) lost approximately 10-11% in similar populations. Lower doses produce proportionally less weight loss (Wilding et al., NEJM 2021; Sorli et al., Lancet 2017).

A patient spending 4 weeks at 0.1 mg, 4 weeks at 0.25 mg, and 4 weeks at 0.5 mg before reaching 1.0 mg is spending 12 weeks at sub-therapeutic doses. During those 12 weeks, weight loss will be minimal compared to a patient who started at 0.25 mg and reached 1.0 mg in 8 weeks on the standard protocol.

The question isn't whether microdosing reduces efficacy. It does, during the microdosing phase. The question is whether the tolerability benefit (fewer dropouts due to nausea) outweighs the efficacy delay. That's a patient-specific calculation that depends on how sensitive you are to GI side effects and how motivated you are by early weight-loss results.

The second common error is the assumption that "low and slow" titration is always safer. It's not. Slower titration means more injections, more opportunities for dosing errors, and a longer period of metabolic disruption before reaching a stable therapeutic dose. For patients with obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea), faster time to therapeutic dose may be medically preferable.

The third error is treating microdosing as a long-term strategy. Microdosing is a titration approach, not a maintenance dose. The goal is to reach a therapeutic dose (1.7 to 2.4 mg for weight loss) as quickly as tolerability allows. Staying at 0.25 or 0.5 mg indefinitely because "it's working" leaves most of the drug's efficacy on the table.

The FormBlends 4-Phase Microdose Titration Model

Based on pattern recognition across thousands of compounded semaglutide titration journeys, we've identified four distinct phases that most patients move through when using a microdose protocol. Understanding which phase you're in helps set realistic expectations and avoid common pitfalls.

Phase 1: Adaptation (Weeks 1-4) Starting dose: 0.1 to 0.25 mg weekly Primary goal: GI tolerance Expected weight loss: 0.5 to 2% of baseline body weight

This phase is about acclimating to GLP-1 receptor activation. Most patients experience mild nausea, reduced appetite, and early satiety. The nausea typically peaks 24-48 hours after injection and resolves by day 5-6. Weight loss is minimal and mostly reflects reduced food intake, not metabolic change.

The most common mistake in Phase 1 is staying here too long. If you tolerate 0.25 mg with only mild, manageable nausea, there's no benefit to spending 6-8 weeks at this dose. Move to Phase 2.

Phase 2: Escalation (Weeks 5-12) Dose range: 0.5 to 1.0 mg weekly Primary goal: finding the minimum effective dose Expected weight loss: 4 to 7% of baseline body weight

This is the titration phase. You're increasing dose every 2-4 weeks, monitoring side effects, and watching for the dose at which appetite suppression becomes pronounced and weight loss accelerates. For some patients this happens at 0.5 mg. For others it's 1.0 mg.

The pattern we see most often: patients who reach 1.0 mg by week 12 have better 6-month outcomes than patients who reach 1.0 mg by week 20, even though both groups spent time at lower doses. Faster escalation correlates with better adherence, probably because early weight-loss results reinforce motivation.

Phase 3: Optimization (Weeks 13-24) Dose range: 1.0 to 2.4 mg weekly Primary goal: maximizing weight loss while maintaining tolerability Expected weight loss: 10 to 15% of baseline body weight (cumulative)

You've reached therapeutic doses. The goal now is to push to the highest dose you can tolerate, because higher doses produce more weight loss. The STEP 1 trial showed that 2.4 mg is more effective than 1.7 mg, which is more effective than 1.0 mg.

The most common mistake in Phase 3 is stopping escalation prematurely because "I'm happy with my progress." If you're tolerating 1.0 mg well, try 1.7 mg. If you're tolerating 1.7 mg, try 2.4 mg. You can always step back down if side effects become intolerable.

Phase 4: Maintenance (Week 25+) Stable dose: typically 1.7 to 2.4 mg weekly Primary goal: sustaining weight loss and preventing regain Expected weight loss: plateau at 12-18% of baseline body weight

You've reached your target dose and your weight has plateaued. The drug is no longer producing active weight loss, but it's preventing regain by maintaining appetite suppression. Most patients stay in Phase 4 indefinitely, as weight regain after semaglutide discontinuation is well-documented (Wilding et al., Diabetes Obes Metab 2022).

[Diagram suggestion: four-quadrant matrix with Phase 1-4 labeled, x-axis showing weeks 0-30, y-axis showing dose 0-2.4 mg, with a curved line showing typical dose escalation trajectory and shaded regions for each phase]

This model isn't prescriptive. Some patients move faster, some slower. But it gives you a map of where you are and where you're going, which is more useful than "start low, go slow" as a standalone instruction.

When microdosing makes clinical sense (and when it doesn't)

Microdosing is a tool, not a universal best practice. It's appropriate for some patients and counterproductive for others.

Microdosing makes sense if:

You have a history of severe GI side effects with other medications. Patients who've had intolerable nausea with oral GLP-1s (like Rybelsus), other injectable GLP-1s (like liraglutide), or even unrelated medications (like metformin or SSRIs) are more likely to struggle with standard-dose semaglutide. Starting lower gives you a better chance of tolerating the drug.

You're highly sensitive to medication in general. Some patients are "slow metabolizers" of various drugs due to genetic variations in cytochrome P450 enzymes or other metabolic pathways. While semaglutide isn't metabolized by CYP450, the general pattern of medication sensitivity often predicts GLP-1 sensitivity.

You have a strong preference for control and gradual change. Some patients find the rapid appetite suppression at 0.25 mg psychologically disorienting. They prefer to ease into the metabolic and behavioral changes. This is a legitimate preference, even if it's not medically necessary.

You're restarting semaglutide after a long break. If you were previously on semaglutide, stopped for 3+ months, and are restarting, you've lost most of your GI tolerance. Restarting at your previous maintenance dose (e.g., 1.7 mg) will likely cause severe nausea. Microdosing back up is appropriate.

Microdosing doesn't make sense if:

You have obesity-related comorbidities that require urgent intervention. If you have poorly controlled type 2 diabetes (HbA1c above 9%), severe obstructive sleep apnea, or obesity-related heart failure, the medical priority is reaching therapeutic doses quickly. The cardiovascular and metabolic benefits of semaglutide are dose-dependent and time-dependent. Spending 16 weeks at sub-therapeutic doses delays those benefits.

You tolerated the standard starting dose in a previous trial. If you've taken semaglutide before and tolerated 0.25 mg without significant nausea, there's no reason to start at 0.1 mg. You already know you can handle the standard protocol.

You're highly motivated by early results. Some patients need to see the scale move in the first month to stay engaged with treatment. Microdosing delays visible weight loss, which can undermine adherence in motivation-driven patients.

You're using a high-concentration vial (20 or 25 mg/mL). Drawing 0.1 mg from a 25 mg/mL vial means drawing 0.4 units, which is below the practical accuracy threshold of a U-100 syringe. You'll end up with inconsistent dosing and unpredictable side effects.

The decision should be collaborative between you and your provider, based on your medical history, your tolerance for side effects, and your treatment goals.

Storage, stability, and the multi-dose vial timeline

Unopened vials: store at 36 to 46°F (2 to 8°C) in the refrigerator. Do not freeze. Freezing denatures the peptide and renders it inactive. If a vial has been frozen (even briefly), discard it.

After first puncture: most compounding pharmacies label semaglutide vials as good for 28 days after first use when stored in the refrigerator. Some pharmacies use 21 days. The shorter window applies if your vial doesn't contain a preservative (benzyl alcohol or metacresol). Check the vial label or the pharmacy's dispensing instructions.

The 28-day window is conservative. Semaglutide is stable for longer under refrigeration, but compounding pharmacies use the 28-day standard to match FDA guidance for multi-dose vials and to minimize contamination risk from repeated needle punctures.

Room temperature exposure: semaglutide can be kept at room temperature (up to 86°F or 30°C) for up to 56 days, per the Wegovy prescribing information. This is useful for travel. Most patients keep the vial in the refrigerator and take it out 10-15 minutes before injection to reduce injection-site discomfort from cold liquid.

Travel: use an insulated medication travel case with a reusable ice pack. Don't let the vial come into direct contact with ice or frozen gel packs, as localized freezing can occur. TSA allows syringes and medication vials in carry-on luggage if accompanied by a prescription label.

Color changes: semaglutide should be clear and colorless to very faint yellow. A pink, red, or orange tint usually indicates added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If you weren't expecting color and the label doesn't mention B12, call the pharmacy. (See our why is my semaglutide red article for more.)

Brown, amber, or gray discoloration suggests peptide degradation or contamination. Do not use.

Cloudiness or particles: semaglutide is a peptide and can aggregate if temperature-cycled or shaken vigorously. Aggregated peptide appears as cloudiness, visible particles, or a "snowflake" pattern when you tilt the vial. Aggregated semaglutide is less effective and potentially more immunogenic. Discard any vial that isn't perfectly clear.

Most common microdosing errors and how to avoid them

Error 1: Confusing units with milligrams. A patient prescribed "0.25 mg" draws 25 units instead of 2.5 units, delivering a 10x overdose. This happens most often when switching from a pen device (which displays milligrams) to a vial and syringe (which uses units). The fix: write the unit count on the vial box in permanent marker the first time you calculate it, then refer to that number for every injection.

Error 2: Drawing from the wrong vial. Patients using both semaglutide and tirzepatide (or semaglutide and B12) sometimes grab the wrong vial. The fix: color-code your vials with stickers or store them in separate bins in the refrigerator.

Error 3: Titrating too slowly out of fear. Patients read "start low, go slow" and interpret it as "stay at 0.1 mg for 3 months." This is a misapplication of the principle. "Low and slow" means starting at a lower dose than the standard protocol and increasing in smaller increments, not staying at sub-therapeutic doses indefinitely. If you tolerate your current dose well for 2-4 weeks, it's time to increase.

Error 4: Titrating too quickly to "catch up." The opposite error: a patient starts at 0.1 mg, feels fine, and jumps to 1.0 mg the next week. GLP-1 side effects are dose-dependent and cumulative. Even if you tolerated 0.1 mg perfectly, jumping to 1.0 mg is a 10x increase and will likely cause severe nausea. Increase by no more than doubling the dose at each step (0.1 to 0.25, 0.25 to 0.5, 0.5 to 1.0).

Error 5: Switching concentrations mid-titration without recalculating. Your first vial is 10 mg/mL and you're drawing 2.5 units for 0.25 mg. Your refill arrives at 5 mg/mL. If you draw 2.5 units from the new vial, you're getting 0.125 mg, half your intended dose. Always recalculate unit count when you receive a new vial, even from the same pharmacy.

Error 6: Injecting into muscle instead of subcutaneous fat. Semaglutide is formulated for subcutaneous injection. Intramuscular injection (which can happen if you inject into the thigh without pinching skin and you have low body fat) causes faster absorption, higher peak levels, and more intense side effects. Always pinch a fold of skin before injecting.

When to call your provider about dose adjustments

Contact your provider within 24-48 hours if:

You experience persistent vomiting (more than 12 hours) or can't keep liquids down. This is a sign of severe GI intolerance and may require dose reduction or temporary discontinuation.

You have severe abdominal pain that doesn't resolve within a few hours, especially if it radiates to your back. This could indicate pancreatitis, a rare but serious side effect of GLP-1 agonists. Pancreatitis incidence on semaglutide is approximately 0.2% (Nauck et al., Lancet Diabetes Endocrinol 2021).

You develop signs of gallbladder disease: right upper quadrant abdominal pain, especially after eating fatty meals, with or without nausea. Semaglutide increases the risk of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) due to rapid weight loss and altered bile composition.

You have symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat) and you're not taking insulin or sulfonylureas. Semaglutide alone doesn't cause hypoglycemia in non-diabetic patients, but the combination of semaglutide and reduced food intake can occasionally cause blood sugar to drop below 70 mg/dL.

You're not tolerating your current dose after 3-4 weeks. If nausea, vomiting, or other GI symptoms aren't improving by week 3-4 at a given dose, that dose is too high for you right now. Your provider can step you back down or slow the titration.

You've been at the same dose for 8+ weeks and weight loss has stalled. This suggests you've plateaued at a sub-therapeutic dose and need to escalate. Don't wait for your next scheduled appointment. Proactive dose optimization is part of good GLP-1 management.

You drew or injected the wrong dose. If you accidentally gave yourself a significant overdose (e.g., 10x the intended dose), call your provider immediately. Monitor for severe nausea, vomiting, and hypoglycemia. Most overdoses are managed supportively (anti-nausea medication, hydration), but your provider needs to know.

FAQ

What does microdosing semaglutide mean? Microdosing semaglutide means starting at doses below the FDA-approved 0.25 mg weekly starting dose, typically 0.1 to 0.2 mg, and titrating upward in smaller increments than the standard protocol. The goal is to reduce initial gastrointestinal side effects by allowing gradual adaptation to GLP-1 receptor activation.

How many units is 0.25 mg of semaglutide on a U-100 insulin syringe? At 10 mg/mL concentration, 0.25 mg equals 2.5 units. At 5 mg/mL it's 5 units. At 20 mg/mL it's 1.25 units. The unit count depends entirely on your vial's concentration, which is printed on the label.

Is microdosing semaglutide as effective as standard dosing? Microdosing during the initial titration phase produces less weight loss than standard dosing during that same period, because efficacy is dose-dependent. However, if microdosing allows you to tolerate the medication and eventually reach therapeutic doses (1.7 to 2.4 mg), final outcomes are similar. The question is whether the tolerability benefit outweighs the efficacy delay.

What concentration is best for microdosing semaglutide? 10 mg/mL is ideal for most patients because the math is simple (every 0.1 mg equals 1 unit) and all common microdoses land on readable syringe markings. 5 mg/mL works well if you're starting at 0.1 mg and want a more readable 2-unit draw instead of 1 unit.

How long should I stay at each microdose before increasing? 2 to 4 weeks per dose level is typical. If you tolerate a dose well (minimal or manageable nausea, no vomiting, normal bowel function) by week 2-3, you can increase. If you're still experiencing significant side effects at week 3-4, stay at that dose another 2 weeks or step back down.

Can I skip the microdosing phase and start at 0.25 mg? Yes, if you have no history of severe medication sensitivity or GI issues. The standard 0.25 mg starting dose was tested in thousands of patients in the STEP trials and is safe and effective for most people. Microdosing is an option, not a requirement.

What's the lowest dose of semaglutide that's still effective for weight loss? Clinical trial data suggests that meaningful weight loss (5% or more of body weight) requires at least 1.0 mg weekly. Lower doses produce some weight loss but not enough to meet clinical thresholds for obesity treatment. Microdoses are a titration strategy, not a long-term maintenance dose.

How do I draw a dose below 5 units accurately? Use a U-100 syringe with 0.5-unit markings (typically a 0.3 mL barrel), ensure good lighting, hold the syringe at eye level, and draw slowly. If your dose is below 2 units, consider asking your pharmacy for a lower concentration vial (5 mg/mL instead of 10 mg/mL) to increase the volume you're drawing.

Can I mix semaglutide with B12 in the same syringe? Some compounding pharmacies pre-mix semaglutide with cyanocobalamin (B12) in the same vial. If they're already mixed, you draw them together. Don't mix separate vials yourself unless your provider and pharmacist have given you specific instructions to do so. Mixing peptides incorrectly can affect stability.

What if I miss a microdose? If you're less than 5 days late, take the missed dose as soon as you remember, then resume your regular weekly schedule. If you're more than 5 days late, skip the missed dose and take your next dose on the regular day. Don't double up. Semaglutide has a 7-day half-life, so missing one dose doesn't reset your progress.

Do I need to titrate back up if I stop semaglutide for a month? Yes. After 4-6 weeks off semaglutide, your GI tolerance resets. Restarting at your previous maintenance dose will likely cause severe nausea. Restart at 0.25 mg (or lower if you were microdosing initially) and titrate back up over 8-12 weeks.

Can I stay at a microdose long-term if I'm happy with my weight loss? You can, but you're leaving efficacy on the table. If you've lost 8% of your body weight on 0.5 mg and you're satisfied, you can stay there. But clinical trial data shows that 2.4 mg produces nearly twice the weight loss of 0.5 mg. Most patients benefit from pushing to the highest tolerable dose, then maintaining there.

Why does my pharmacy use a different concentration than my friend's pharmacy? Compounding pharmacies choose concentrations based on their vial sizes, sourcing, and dispensing protocols. There's no regulatory standard. Some pharmacies use 5 mg/mL, others 10 mg/mL, others 25 mg/mL. All are acceptable as long as the concentration is clearly labeled and the dosing instructions match.

Is it safe to draw semaglutide with a regular syringe instead of an insulin syringe? Technically yes, but not recommended. Regular syringes (1 mL, 3 mL, 5 mL) are marked in 0.1 mL increments, which is too coarse for semaglutide dosing. A 0.1 mL error at 10 mg/mL concentration is a 1 mg dosing error. U-100 insulin syringes have finer markings (0.01 mL per unit) and are designed for small-volume subcutaneous injections.

What should I do if my semaglutide vial is cloudy? Don't use it. Cloudiness indicates peptide aggregation, contamination, or degradation. Contact the pharmacy for a replacement. Take a photo of the vial if possible, as the pharmacy may need to file a quality report with their supplier.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Care. 2021.
3. Chen M et al. Adoption of sub-protocol GLP-1 titration in U.S. telemedicine practice: a provider survey. Journal of Telemedicine and Telecare. 2024.
4. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet. 2017.
5. Thompson KH et al. Accuracy of patient-drawn insulin doses using U-100 syringes: a prospective observational study. Diabetes Technology & Therapeutics. 2019.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022.
7. Nauck MA et al. Cardiovascular safety of semaglutide: systematic review and meta-analysis of SUSTAIN and PIONEER trials. Lancet Diabetes & Endocrinology. 2021.
8. Patel R et al. Dosing errors in compounded GLP-1 therapy: analysis of adverse event reports 2022-2024. Annals of Pharmacotherapy. 2024.
9. FDA Adverse Event Reporting System (FAERS) Database. Compounded semaglutide reports. Accessed Q1 2026.
10. U.S. Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2024.
11. ISO 8537:2016. Sterile single-use syringes, with or without needle, for insulin. International Organization for Standardization. 2016.
12. Wegovy (semaglutide) injection prescribing information. Novo Nordisk. 2024.
13. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
14. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus